SCHEMBL24329369

SCHEMBL24329369

Cc1cn(C)nc1C(=O)Nc1nc2cccnc2s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.53
RAB9A P51151 6/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
KDM4E B2RXH2 3/20 0.53
POLB P06746 3/20 0.46
KMT2A Q03164 2/20 0.46
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 1/20 0.46
HPGD P15428 1/20 0.46
LMNA P02545 5/20 0.46
MITF O75030 1/20 0.45
MAPT P10636 9/20 0.44
CACNA1B Q00975 1/20 0.44
APBA1 Q02410 1/20 0.44
HTT P42858 3/20 0.43
S1PR4 O95977 2/20 0.43
S1PR1 P21453 2/20 0.43
OPRK1 P41145 1/20 0.43
TP53 P04637 2/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26603055 0.81 POLB (0.48) NPC1RAB9ASMN1; SMN2KDM4EPOLB
SCHEMBL24329695 0.77 RAB9A (0.60) NPC1RAB9ASMN1; SMN2KDM4EPOLB
SCHEMBL24329368 0.77 NPC1 (0.56) NPC1RAB9ASMN1; SMN2KDM4EPOLB
SCHEMBL185171 0.76 DYRK1A (0.60) NPC1RAB9ASMN1; SMN2POLBKMT2A
SCHEMBL24329832 0.72 NPC1 (0.44) NPC1RAB9ASMN1; SMN2KDM4EPOLB
SCHEMBL24329370 0.71 NPC1 (0.43) NPC1RAB9ASMN1; SMN2KDM4EPOLB
SCHEMBL5740431 0.71 RAB9A (0.70) NPC1RAB9ASMN1; SMN2KDM4EKMT2A
SCHEMBL24329367 0.70 HCRTR1 (0.43) NPC1RAB9ASMN1; SMN2KDM4EPOLB
SCHEMBL4920630 0.69 NPC1 (0.74) NPC1RAB9ASMN1; SMN2KDM4EKMT2A
SCHEMBL4917553 0.69 NPC1 (1.00) NPC1RAB9ASMN1; SMN2KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 US disclosed
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 US disclosed
WO-2022082071-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF US THEREOF CARTHRONIX, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF STAT1, STAT3, STAT6 NPC1 2133/4885RAB9A 3504/4885SMN1; SMN2 4696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.